Clinical trials: Typhoid and Paratyphoid Fevers

Typhoid Fever

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

• Completed
• Age: 18 to 50 years
• Phase 1
• Vaccines
• Injection or infusion
• Results posted

A bivalent Typhoid and Paratyphoid A conjugate investigational vaccine aimed to prevent both typhoid and paratyphoid enteric fever in infants and older age groups has been developed by GlaxoSmithKline (GSK).

Trial name

NCT05613205

Testing

TYP04A Low Dose without Alum investigational vaccine, TYP04B Full Dose without Alum investigational vaccine, TYP03A Low Dose with Alum investigational vaccine

Where

Belgium

Volunteers

97 people, healthy volunteers welcome

Sponsor

GlaxoSmithKline